henhaobio
Sign in

bioRxivMicrobiologyPreprint

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Gajanan N. SapkaliD, Pragya Dhruv YadaviD, Raches EllaiD, Gururaj Rao DeshpandeiD, Rima Rakeshkumar SahayiD, Nivedita GuptaiD, Viswanathan MohaniD, Priya AbrahamiD, Samiran PandaiD, Balram BhargavaiD

PDFDOI
Structured summary available · Jump to summary ↓

Abstract

We performed the plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.

Abstract summary

Claude Opus 5.5 · xhigh effort · 18 Oct 2026 · from the abstract · CC BY-NC 4.0

Sera from 26 BBV152/COVAXIN recipients neutralised the UK variant about as well as a heterologous strain in plaque reduction tests, arguing against escape from vaccine-induced antibodies.

The UK variant raised the worry that antibodies raised by vaccination would neutralise it less well. This note tests sera from recipients of one vaccine, BBV152/COVAXIN, against that variant alongside a heterologous strain.

Key results

  1. SuggestedVaccinee sera neutralised the UK variant isolate with efficiency comparable to the heterologous isolate.

    Plaque reduction neutralization test (PRNT50) on sera from 26 BBV152/COVAXIN recipients against hCoV-19/India/20203522 and the second isolate; the abstract reports the comparison qualitatively and gives no titres, ratios or confidence intervals. · Abstract

  2. ClaimedThe authors read this as removing the concern that the UK variant escapes neutralisation by this vaccine.

    Conclusion stated directly from the comparable neutralisation activity; no escape threshold, fold-change cutoff or clinical outcome data is presented. · Abstract

Methods, data and reproducibility

Serum from vaccinated individuals was assayed by plaque reduction neutralization test (PRNT50) against a UK-variant virus isolate and a heterologous strain, and the resulting neutralisation activities were compared.

  • Sera from recipients of the BBV152/COVAXIN vaccine · human · n = 26 recipients
  • UK-variant virus isolate hCoV-19/India/20203522 used in the neutralization test · virus
  • Heterologous virus isolate, written in the text as hCoV27 19/India/2020Q111 · virus
Methods & tools
plaque reduction neutralization test (PRNT50), BBV152/COVAXIN
Reproducibility gaps
No data repository, raw titre table or code is referenced in the abstract.
Limitations (2)
  • Only 26 vaccinated donors were tested, and the abstract gives no numeric titres, so the size of any difference between the two isolates cannot be assessed. · noted in this summary
  • A single vaccine and two virus isolates are compared in vitro; neutralisation in the assay is not linked here to protection from infection or disease. · noted in this summary

Read this if you track whether emerging coronavirus variants evade vaccine-induced neutralisation and want the serology for BBV152/COVAXIN against the UK variant.

Citations
55

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Related papers

Similarity Map
SelectedSame fieldCross-field
THISMarot '21Yadav '21Sapkal '21Yadav '21Yadav '21Abdoli '22
73% semantic matchMicrobiology
S. S. Marot, I. Malet, A. Jary+12 more·bioRxiv·Mar 5, 2021